News


All series


All News

A combined regimen of pazopanib and trametinib was tolerable at full single-agent doses in patients with differentiated thyroid cancer according to the results of a multicenter phase I trial expansion cohort. The expansion cohort showed that the combination has clinical activity in DTC but did not achieve the pre-specified response rate, according to a new report in&nbsp;<em>Clinical Cancer Research</em>.

Testosterone suppression with docetaxel, the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC), was combined with chemotherapy or enzalutamide (Xtandi) to assess the potential improvement in overall survival compared with non-steroidal anti-androgens like bicalutamide, nilutamide, and flutamide in the&nbsp;phase III ENZAMET trial.&nbsp;<br /> &nbsp;

Jane Lowe Meisel, MD, reviewed systemic therapy options for treating patients with breast cancer with a group of physicians during a&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives discussion. Meisel explained the treatment considerations she makes for treating patients with breast cancer during the dinner event in terms of 2 case studies.

A single-arm, multicenter phase II trial held in China analyzed the Bruton&rsquo;s tyrosine kinase inhibitor zanubrutinib for treatment of patients with relapsed/refractory mantle cell lymphoma. Previously, the investigational BTK inhibitor gained a&nbsp;breakthrough&nbsp;designation&nbsp;from the&nbsp;FDA&nbsp;based on early results from the phase II trial that showed zanubrutinib to be highly active.<br /> &nbsp;

In the phase III PRIMA trial, niraparib demonstrated a benefit in progression-free survival compared with placebo when used as maintenance therapy following platinum-based chemotherapy for patients with ovarian cancer treated in the first line.&nbsp;The PFS benefit was found to be statistically significant, regardless of patients&rsquo; biomarker status, meeting the primary endpoint of the trial.&nbsp;

The Association of Community Cancer Centers has launched the Barriers to Quality Care in Ovarian Cancer project, a collaboration with AstraZeneca, Merck, and partners including the Association for Molecular Pathology, the National Society of Genetic Counselors, and the Society of Gynecologic Oncology. The project aims to understand the key issues associated with ovarian cancer care and provide guidance to help cancer centers implement better care for patients diagnosed with epithelial ovarian cancer.&nbsp;

The 4-drug regimen of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone induced a high percentage of stringent complete responses compared with VRd alone in patients with newly diagnosed multiple myeloma who are eligible for high-dose chemotherapy and an autologous stem cell transplantation, according to topline results of the GRIFFIN trial. This met the primary endpoint of the phase II trial.

The FDA has granted a fast track designation for CLR 131 as a potential treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. The designation was based on data from the DLBCL cohort of the ongoing phase II CLOVER-1 trial which is investigating CLR 131 in patients with relapsed/refractory B-cell lymphomas.

Updated results from an interim analysis of the phase III BEACON CRC trial demonstrated a significant improvement in overall survival for the triplet regimen of encorafenib, binimetinib, and cetuximab compared with cetuximab and irinotecan-containing regimens in patients with previously treated&nbsp;<em>BRAF&nbsp;</em>V600E&ndash;mutant metastatic colorectal cancer.

Treatment with erlotinib significantly extended progression-free survival in patients with stage IIIA-N2&nbsp;<em>EGFR-</em>mutant non&ndash;small cell lung cancer compared with a combined chemotherapy regimen of gemcitabine plus cisplatin, according to clinical trial results published recently in the&nbsp;<em>Journal of Clinical Oncology</em>.